- Australia. Department of Health Housing and Community Services. Guidelines for the pharmaceutical industry on the preparation of submissions to the Pharmaceutical Benefits Advisory Committee. Canberra: AGPS, 1992
- Australia. Department of Health and Ageing. Guidelines for the pharmaceutical industry on preparation of submissions to the Pharmaceutical Benefits Advisory Committee. Canberra: September, 2002
- United Kingdom. National Institute for Clinical Excellence. Guidelines for manufacturers and sponsors. Technology Appraisal series No. 5. London: NICE, June 2001
- United Kingdom. National Institute for Clinical Excellence. Guide to the Methods of Technology Appraisal (Consultation draft, August 2003)
- Langley PC, Martin RE, Burton E. Guidelines for Formulary Submission. Integrated Pharmaceutical Services and Foundation Health Corporation, Rancho Cordova, CA, October 1966
- Regence Washington Health Pharmacy Services. Guidelines for the submission of clinical and economic data supporting formulary consideration. Regence Washington Health, University of Washington, Seattle 1997
- Langley PC. Guidelines for formulary submissions for pharmaceutical product evaluation. Blue Cross and Blue Shield of Colorado and Nevada. Denver CO, October 1998
- Academy of Managed Care Pharmacy. Format for Formulary Submissions Version 2.0. AMCP, October 2002
- DiMasi JA, Caglarcan E, Wood-Armany M. Emerging role of pharmacoeconomics in the research and development decision-making process. Pharmacoeconomics 2001;19:753–66
- DiMasi JA. Risks in new drug development: approval success rates for investigational drugs. Clin Pharmacol Ther 2001;69: 297–307
- DiMasi JA. The value of improving the productivity of the drug development process. Pharmacoeconomics 2002;20 (Suppl 3):1–10
- Langley PC. Health Economics in the Drug Life Cycle. London: Urch Publishing, 2002
Current Medical Research and Opinion
Volume 20, 2004 - Issue 2